Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vir Biotechnology Inc V.VIR


Primary Symbol: VIR

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.


NDAQ:VIR - Post by User

Post by PaperStackson Jan 07, 2020 12:02pm
452 Views
Post# 30526293

Rough Times Continue at EXP

Rough Times Continue at EXP

With Jay (commonly known on these boards as "the Slouch") gone, that's a step in a positive direction given at his control the company  value fell by ~90%. But having him replaced with Jarrett seem odd, under Jarrett's control as CEO the company had a burn rate that left them with months of liquidity before going insolvent (as per the financial reports dung his tenure).

Let's see how the Q4 looks, sure it will be a steaming pile with burn rates vs cash flow that will have EXP again facing bankruptcy (probably within 2020 given the Q3 results). Speaking of which, where are the Q4 results? Year end is November.

Where is the Process Sales license? Weren't they suppose to ship to QC in December 2019? Why spend share holder money on extraction capabilities if you can't sell any processed products? They have had the Process License since Aug 2018, isn't worth much without the ability to sell and start cashlfowing another channel.
At this rate it's hard to envision EXP making it past 2020 - imo.

<< Previous
Bullboard Posts
Next >>